Accelerate safer, smarter drug discovery
With over 50% of Phase II and III trials failing due to efficacy, and 25% due to safety , it’s never been more critical to reduce risk early.
OFF-X and Cortellis Drug Discovery Intelligence help R&D teams accelerate preclinical decisions and improve their odds of success by anticipating safety issues and validating the right targets earlier.
Request more information
A complete intelligence solution for modern drug discovery
Cortellis Drug Discovery Intelligence and OFF-X are built for drug discovery, preclinical and translational professionals who need a holistic, translational approach to optimize early-stage research.
Unlike fragmented alternatives, this combined solution offers broad and deep coverage of biology, pharmacology, chemistry, and toxicity data — integrated across the full drug development lifecycle.
Why combine OFF-X and Cortellis?
With increasing investor pressure and flat success rates, every failed trial costs more. OFF-X and Cortellis give you the insight you need to avoid those failures and the confidence to move faster with less risk.
- OFF-X equips you to anticipate safety risks for targets and compounds, from discovery to post-market.
- Cortellis Drug Discovery Intelligence provides rich biological, pharmacological, and competitive insights to drive target selection and compound optimization.
- Together, they help reduce late-stage failures, prioritize safer, more promising targets, compare experimental data and anticipate adverse events, design smarter early-phase trials.

Explore key features
OFF-X highlights:
- Safety profiles of 40,000+ drugs and biologics
- Monitor adverse events daily from regulatory and literature sources
- Benchmark class effects, analyze pathways, explore population-specific risks
Cortellis Drug Discovery Intelligence highlights:
- Validate targets using disease association scoring
- Access biology, chemistry, and pharmacology data in one place
- Optimize compounds with synthesis tools, IP insights, and biomarker data
OFF-X and Cortellis Drug Discovery Intelligence combined, the platforms cover:
- 49k+ genes & targets
- 3m+ curated safety alerts
- 6500+ diseases
- 3.1m+ publications and 589k+ patents